Takeover rumors ON GOOGLE16 Feb 2026 21:14
Based on recent updates as of February 2026, ImmuPharma PLC (LSE: IMM) is a London-based drug discovery company with a primary focus on developing treatments for autoimmune diseases, particularly Lupus.
Current Status and Key Developments (As of Feb 2026):
Takeover Speculation: There has been market chatter that a potential 65 pence per share takeover offer was rejected by the company.
Share Price: As of mid-February 2026, the share price has been trading in a range often discussed around the 6p-7p mark, with a 52-week range indicating volatility (low of ~1.39p to high of 19.40p).
P140 (Lupuzor™) Partnership Discussions: ImmuPharma is actively working on securing a partnership for P140, their lead, first-in-class, peptide-based immunomodulator for lupus.
Timeline Update: While previously targeting the end of 2025, the company announced in late 2025 that it expects to finalize a partnership deal in 2026.
Financial Position: Following funding arrangements, the company reported having sufficient cash to operate well into the final quarter of 2026, with no immediate plans for new fundraising.
Clinical Focus: Beyond Lupuzor, the company is developing P140 for other autoimmune indications (e.g., CIDP) and has a promising early-stage cancer candidate, IPP204106.
Context on 65p Mentions:
Based on historical stock market chat and analysis, mentions of "65p" in relation to ImmuPharma often refer to historic, speculative, or long-term target prices discussed by investors, or old takeover rumors.
As of Feb 2026, the stock is trading well below that level, with discussions focused on achieving a partnership to drive value.
Share Price Targets: Some market discussions suggest that if a deal is successful, a price range of 40-65 pence is possible
Sign In
Follow the stocks
